Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 346 AL 358

A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease

McGhee DJ, Ritchie CW, Zajicek JP, Counsell CE.

BMC Neurol. 2016 Jun 16;16:92. doi: 10.1186/s12883-016-0606-3.

Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases

Parnetti L, Eusebi P, Lleó A.

Front Neurol Neurosci. 2016;39:117-23. doi: 10.1159/000445452. Epub 2016 Jul 26.

Metals in Alzheimer's and Parkinson's Disease: Relevance to Dementia with Lewy Bodies

McAllum EJ, Finkelstein DI.

J Mol Neurosci. 2016 Nov;60(3):279-288. doi: 10.1007/s12031-016-0809-5. Epub 2016 Aug 8.

Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems

Cunha S, Amaral MH, Lobo JM, Silva AC.

Curr Med Chem. 2016;23(31):3618-3631. doi: 10.2174/0929867323666160824162401.

Toxin-Induced Experimental Models of Learning and Memory Impairment

More SV, Kumar H, Cho DY, Yun YS, Choi DK.

Int J Mol Sci. 2016 Sep 1;17(9):1447. doi: 10.3390/ijms17091447.

Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease

Jiang T, Sun Q, Chen S.

Prog Neurobiol. 2016 Dec;147:1-19. doi: 10.1016/j.pneurobio.2016.07.005. Epub 2016 Oct 18.

Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases

Van der Schyf CJ.

Drug Dev Res. 2016 Dec;77(8):458-468. doi: 10.1002/ddr.21368. Epub 2016 Nov 4.

Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics

Belaidi AA, Bush AI.

J Neurochem. 2016 Oct;139 Suppl 1:179-197. doi: 10.1111/jnc.13425. Epub 2016 Feb 10.

Endocannabinoid System in Neurological Disorders

Ranieri R, Laezza C, Bifulco M, Marasco D, Malfitano AM.

Recent Pat CNS Drug Discov. 2016;10(2):90-112. doi: 10.2174/1574889810999160719105433.

[A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy]

Pupyshev AB, Korolenko TA, Tikhonova MA.

Zh Vyssh Nerv Deiat Im I P Pavlova. 2016 Sep;66(5):515-540.

The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review

Manoharan S, Guillemin GJ, Abiramasundari RS, Essa MM, Akbar M, Akbar MD.

Oxid Med Cell Longev. 2016;2016:8590578. doi: 10.1155/2016/8590578. Epub 2016 Dec 27.

Purinergic receptors as potential therapeutic targets in Alzheimer's disease

Woods LT, Ajit D, Camden JM, Erb L, Weisman GA.

Neuropharmacology. 2016 May;104:169-79. doi: 10.1016/j.neuropharm.2015.10.031. Epub 2015 Oct 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias